{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,20]],"date-time":"2024-07-20T02:59:13Z","timestamp":1721444353932},"reference-count":41,"publisher":"Spandidos Publications","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mol Med Report"],"DOI":"10.3892\/mmr.2019.10539","type":"journal-article","created":{"date-parts":[[2019,7,31]],"date-time":"2019-07-31T06:28:20Z","timestamp":1564554500000},"source":"Crossref","is-referenced-by-count":0,"title":["Homoharringtonine enhances the effect of imatinib on chronic myelogenous leukemia cells by downregulating ZFX"],"prefix":"10.3892","author":[{"given":"Jingjing","family":"Wu","sequence":"first","affiliation":[{"name":"Department of Hematology, The Affiliated Huai'an No. 1 People's Hospital of Nanjing Medical University, Huai'an, Jiangsu 223300, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bin","family":"Wei","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Affiliated Huai'an No. 1 People's Hospital of Nanjing Medical University, Huai'an, Jiangsu 223300, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuye","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Affiliated Huai'an No. 1 People's Hospital of Nanjing Medical University, Huai'an, Jiangsu 223300, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xueying","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Affiliated Huai'an No. 1 People's Hospital of Nanjing Medical University, Huai'an, Jiangsu 223300, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yihan","family":"Ding","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Affiliated Huai'an No. 1 People's Hospital of Nanjing Medical University, Huai'an, Jiangsu 223300, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunling","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Affiliated Huai'an No. 1 People's Hospital of Nanjing Medical University, Huai'an, Jiangsu 223300, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yufeng","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Affiliated Huai'an No. 1 People's Hospital of Nanjing Medical University, Huai'an, Jiangsu 223300, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2019,7,31]]},"reference":[{"key":"key20200713233725_b1-mmr-20-04-3233","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1016\/S0140-6736(13)62120-0","article-title":"Chronic myeloid leukaemia","volume":"385","author":"Apperley","year":"2015","journal-title":"Lancet"},{"key":"key20200713233725_b2-mmr-20-04-3233","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1038\/nrc1567","article-title":"Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia","volume":"5","author":"Ren","year":"2005","journal-title":"Nat Rev Cancer"},{"key":"key20200713233725_b3-mmr-20-04-3233","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/sj.leu.2403241","article-title":"JAK\/STAT, Raf\/MEK\/ERK, PI3K\/Akt and BCR-ABL in cell cycle progression and leukemogenesis","volume":"18","author":"Steelman","year":"2004","journal-title":"Leukemia"},{"key":"key20200713233725_b4-mmr-20-04-3233","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1056\/NEJM200104053441402","article-title":"Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia","volume":"344","author":"Druker","year":"2001","journal-title":"N Engl J Med"},{"key":"key20200713233725_b5-mmr-20-04-3233","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1182\/blood-2002-02-0545","article-title":"Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: High incidence of early complete and major cytogenetic responses","volume":"101","author":"Kantarjian","year":"2003","journal-title":"Blood"},{"key":"key20200713233725_b6-mmr-20-04-3233","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.1038\/sj.leu.2402741","article-title":"Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy","volume":"16","author":"Hochhaus","year":"2002","journal-title":"Leukemia"},{"key":"key20200713233725_b7-mmr-20-04-3233","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.clml.2013.03.018","article-title":"Resistance to tyrosine kinase inhibition therapy for chronic myelogenous leukemia: A clinical perspective and emerging treatment options","volume":"13","author":"Jabbour","year":"2013","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"key20200713233725_b8-mmr-20-04-3233","doi-asserted-by":"publisher","first-page":"657","DOI":"10.3892\/mmr_00000153","article-title":"RUNX1T1 is overexpressed in imatinib mesylate-resistant cells","volume":"2","author":"Binato","year":"2009","journal-title":"Mol Med Rep"},{"key":"key20200713233725_b9-mmr-20-04-3233","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1002\/jps.2600610812","article-title":"Antitumor alkaloids for Cephalataxus harringtonia: Structure and activity","volume":"61","author":"Powell","year":"1972","journal-title":"J Pharm Sci"},{"key":"key20200713233725_b10-mmr-20-04-3233","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/1756-8722-7-2","article-title":"Homoharringtonine and omacetaxine for myeloid hematological malignancies","volume":"7","author":"L\u00fc","year":"2014","journal-title":"J Hematol Oncol"},{"key":"key20200713233725_b11-mmr-20-04-3233","doi-asserted-by":"publisher","first-page":"3513","DOI":"10.1200\/JCO.2000.18.20.3513","article-title":"Homoharringtonine and low-dose cytarabine in the management of late chronic-phase chronic myelogenous leukemia","volume":"18","author":"Kantarjian","year":"2000","journal-title":"J Clin Oncol"},{"key":"key20200713233725_b12-mmr-20-04-3233","doi-asserted-by":"publisher","first-page":"2204","DOI":"10.1038\/sj.leu.2404772","article-title":"BCR-ABL(T315I) transcript disappearance in an imatinib-resistant CML patient treated with homoharringtonine: A new therapeutic challenge","volume":"21","author":"Legros","year":"2007","journal-title":"Leukemia"},{"key":"key20200713233725_b13-mmr-20-04-3233","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1016\/j.leukres.2013.06.023","article-title":"\u03b2-Catenin and AKT are promising targets for combination therapy in acute myeloid leukemia","volume":"37","author":"Wang","year":"2013","journal-title":"Leuk Res"},{"key":"key20200713233725_b14-mmr-20-04-3233","doi-asserted-by":"publisher","first-page":"9409","DOI":"10.3892\/mmr.2017.7835","article-title":"Semi-random mutagenesis profile of BCR-ABL during imatinib resistance acquirement in K562 cells","volume":"16","author":"Dong","year":"2017","journal-title":"Mol Med Rep"},{"key":"key20200713233725_b15-mmr-20-04-3233","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1111\/j.1432-1033.1977.tb11256.x","article-title":"Inhibition of translation in eukaryotic systems by harringtonine","volume":"72","author":"Fresno","year":"1977","journal-title":"Eur J Biochem"},{"key":"key20200713233725_b16-mmr-20-04-3233","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.1038\/sj.leu.2402775","article-title":"Drug responses of imatinib mesylate-resistant cells: Synergism of imatinib with other chemotherapeutic drugs","volume":"16","author":"Tipping","year":"2002","journal-title":"Leukemia"},{"key":"key20200713233725_b17-mmr-20-04-3233","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.cell.2007.03.014","article-title":"Zfx controls the self-renewal of embryonic and hematopoietic stem cells","volume":"129","author":"Galan-Caridad","year":"2007","journal-title":"Cell"},{"key":"key20200713233725_b18-mmr-20-04-3233","doi-asserted-by":"publisher","first-page":"e42302","DOI":"10.1371\/journal.pone.0042302","article-title":"ZFX controls the self-renewal of human embryonic stem cells","volume":"7","author":"Harel","year":"2012","journal-title":"PLoS One"},{"key":"key20200713233725_b19-mmr-20-04-3233","doi-asserted-by":"publisher","first-page":"171","DOI":"10.3727\/096504012X13548165987493","article-title":"The role of ZFX in non-small cell lung cancer development","volume":"20","author":"Jiang","year":"2012","journal-title":"Oncol Res"},{"key":"key20200713233725_b20-mmr-20-04-3233","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.canlet.2013.04.003","article-title":"Knockdown of ZFX inhibits gastric cancer cell growth in vitro and in vivo via downregulating the ERK-MAPK pathway","volume":"337","author":"Wu","year":"2013","journal-title":"Cancer Lett"},{"key":"key20200713233725_b21-mmr-20-04-3233","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s11060-012-1032-z","article-title":"ZFX regulates glioma cell proliferation and survival in vitro and in vivo","volume":"112","author":"Zhu","year":"2013","journal-title":"J Neurooncol"},{"key":"key20200713233725_b22-mmr-20-04-3233","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1007\/s00280-014-2379-y","article-title":"shRNA-mediated silencing of ZFX attenuated the proliferation of breast cancer cells","volume":"73","author":"Yang","year":"2014","journal-title":"Cancer Chemother Pharmacol"},{"key":"key20200713233725_b23-mmr-20-04-3233","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/j.celrep.2014.01.007","article-title":"ZFX controls propagation and prevents differentiation of acute T-lymphoblastic and myeloid leukemia","volume":"6","author":"Weisberg","year":"2014","journal-title":"Cell Rep"},{"key":"key20200713233725_b24-mmr-20-04-3233","doi-asserted-by":"publisher","first-page":"3025","DOI":"10.12659\/MSM.897699","article-title":"Effect of over-expression of Zinc-finger protein (ZFX) on self-renewal and drug-resistance of hepatocellular carcinoma","volume":"22","author":"Zhang","year":"2016","journal-title":"Med Sci Monit"},{"key":"key20200713233725_b25-mmr-20-04-3233","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1002\/ijc.28819","article-title":"Overexpression of ZFX confers self-renewal and chemoresistance properties in hepatocellular carcinoma","volume":"135","author":"Lai","year":"2014","journal-title":"Int J Cancer"},{"key":"key20200713233725_b26-mmr-20-04-3233","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s12013-016-0725-x","article-title":"ZFX facilitates cell proliferation and imatinib resistance in chronic myeloid leukemia cells","volume":"74","author":"Wu","year":"2016","journal-title":"Cell Biochem Biophys"},{"key":"key20200713233725_b27-mmr-20-04-3233","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1002\/ijc.28434","article-title":"Bcr-Abl activates AURKA and AURKB in chronic myeloid leukemia cells via AKT signaling","volume":"134","author":"Yang","year":"2014","journal-title":"Int J Cancer"},{"key":"key20200713233725_b28-mmr-20-04-3233","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method","volume":"25","author":"Livak","year":"2001","journal-title":"Methods"},{"key":"key20200713233725_b29-mmr-20-04-3233","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1002\/cyto.a.20030","article-title":"Rapid detection of phosphotyrosine proteins by flow cytometric analysis in Bcr-Abl-positive cells","volume":"62","author":"Desplat","year":"2004","journal-title":"Cytometry A"},{"key":"key20200713233725_b30-mmr-20-04-3233","doi-asserted-by":"publisher","first-page":"765","DOI":"10.3324\/haematol.12186","article-title":"Phospho-CRKL monitoring for the assessment of BCR-ABL activity in imatinib-resistant chronic myeloid leukemia or Ph+ acute lymphoblastic leukemia patients treated with nilotinib","volume":"93","author":"La Ros\u00e9e","year":"2008","journal-title":"Haematologica"},{"key":"key20200713233725_b31-mmr-20-04-3233","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1038\/sj.leu.2403898","article-title":"Compensatory PI3-kinase\/Akt\/mTor activation regulates imatinib resistance development","volume":"19","author":"Burchert","year":"2005","journal-title":"Leukemia"},{"key":"key20200713233725_b32-mmr-20-04-3233","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1517\/14656566.2014.850491","article-title":"Resistant chronic myeloid leukemia beyond tyrosine-kinase inhibitor therapy: Which role for omacetaxine","volume":"15","author":"Visani","year":"2014","journal-title":"Expert Opin Pharmacother"},{"key":"key20200713233725_b33-mmr-20-04-3233","doi-asserted-by":"publisher","first-page":"2573","DOI":"10.1182\/blood-2012-03-415307","article-title":"Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation","volume":"120","author":"Cortes","year":"2012","journal-title":"Blood"},{"key":"key20200713233725_b34-mmr-20-04-3233","first-page":"80","article-title":"Effect of homoharringtonine combined with Imatinib on the K562\/G01 cells and its mechanism","volume":"25","author":"Wu","year":"2017","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"key":"key20200713233725_b35-mmr-20-04-3233","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1111\/j.1600-0609.2008.01116.x","article-title":"Homoharringtonine affects the JAK2-STAT5 signal pathway through alteration of protein tyrosine kinase phosphorylation in acute myeloid leukemia cells","volume":"81","author":"Tong","year":"2008","journal-title":"Eur J Haematol"},{"key":"key20200713233725_b36-mmr-20-04-3233","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.exphem.2008.11.005","article-title":"Optimization of methods for the detection of BCR-ABL activity in Philadelphia-positive cells","volume":"37","author":"Hamilton","year":"2009","journal-title":"Exp Hematol"},{"key":"key20200713233725_b37-mmr-20-04-3233","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1038\/leu.2009.52","article-title":"Inhibitory effects of omacetaxine on leukemic stem cells and BCR-ABL-induced chronic myeloid leukemia and acute lymphoblastic leukemia in mice","volume":"23","author":"Chen","year":"2009","journal-title":"Leukemia"},{"key":"key20200713233725_b38-mmr-20-04-3233","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1080\/10428190802320368","article-title":"Homoharringtonine inhibits the AKT pathway and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells","volume":"49","author":"Meng","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"key20200713233725_b39-mmr-20-04-3233","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1038\/cgt.2012.53","article-title":"Knockdown of zinc finger protein X-linked inhibits prostate cancer cell proliferation and induces apoptosis by activating caspase-3 and caspase-9","volume":"19","author":"Jiang","year":"2012","journal-title":"Cancer Gene Ther"},{"key":"key20200713233725_b40-mmr-20-04-3233","first-page":"2460","article-title":"ZFX knockdown inhibits growth and migration of non-small cell lung carcinoma cell line H1299","volume":"6","author":"Li","year":"2013","journal-title":"Int J Clin Exp Pathol"},{"key":"key20200713233725_b41-mmr-20-04-3233","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.cancergen.2014.08.007","article-title":"Knockdown of ZFX suppresses renal carcinoma cell growth and induces apoptosis","volume":"207","author":"Fang","year":"2014","journal-title":"Cancer Genet"}],"container-title":["Molecular Medicine Reports"],"original-title":[],"deposited":{"date-parts":[[2020,7,14]],"date-time":"2020-07-14T00:35:01Z","timestamp":1594686901000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/mmr.2019.10539"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,31]]},"references-count":41,"URL":"https:\/\/doi.org\/10.3892\/mmr.2019.10539","relation":{},"ISSN":["1791-2997","1791-3004"],"issn-type":[{"value":"1791-2997","type":"print"},{"value":"1791-3004","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,31]]}}}